Photo: Ismael Francisco/Cubadebate/Archive.

The study uses the Soberana 01 vaccine candidate, the first to receive authorization in Cuba for tests on human beings, and seeks to “stimulate protective levels of neutralizing antibodies against possible reinfection.”

by OnCuba Staff January 26, 2021 in Cuba

Cuba is carrying out a clinical trial in people convalescing from COVID-19, who had a minor clinical picture or were asymptomatic, the official media reported.

The study uses the Soberana 01 vaccine candidate, the first to receive authorization in Cuba for tests on human beings, and seeks to “stimulate protective levels of neutralizing antibodies against possible reinfection,” Prensa Latina (PL) agency reported.

The agency recalled that “globally there are cases of people infected with this coronavirus who were reinfected, even with much more acute and serious forms of the disease,” which is why the trial that is taking place on the island “also seeks to protect this risk group.”

The test began on January 9 at the Institute of Hematology and Immunology and involves 30 volunteers, aged 19 to 59, “who were in contact with the virus and currently have a negative PCR.” These people received a single dose of the vaccine on day 16 and “from that moment on, they are being closely monitored through doctor’s offices and direct contact with the researchers.”

Dr. Rolando Ochoa, a specialist in Immunology at the Finlay Vaccine Institute, explained that the formulation of Soberana 01 used in the test “is simpler and safer, according to the characteristics of the population group under study.”

By US-Cuba Normalization Committee

Organizing Committee, International and Nationwide Conference for the Normalization of US-Cuba Relations.

28 thoughts on “Clinical trial in people convalescing from COVID-19 carried out in Cuba”
  1. An interesting discussion is worth comment. There’s no doubt that that you need to publish more about this topic, it might not be a taboo matter but usually people don’t speak about these issues. To the next! Cheers!!

  2. I absolutely love your site.. Pleasant colors & theme. Did you create this amazing site yourself? Please reply back as Iím looking to create my very own website and would like to learn where you got this from or exactly what the theme is called. Cheers!

  3. Oh my goodness! Amazing article dude! Thanks, However I am going through troubles with your RSS. I donít understand the reason why I am unable to subscribe to it. Is there anybody having identical RSS problems? Anybody who knows the solution can you kindly respond? Thanx!!

  4. I used to be recommended this website by my cousin. I am not sure whether this put
    up is written by means of him as nobody else know
    such unique approximately my trouble. You’re wonderful!

    Thanks!

  5. Hi! Do you know if they make any plugins to help with SEO?
    I’m trying to get my blog to rank for some targeted keywords
    but I’m not seeing very good success. If you know of any please
    share. Appreciate it!

  6. I don’t know if it’s just me or if perhaps everybody else experiencing issues with your site.
    It appears like some of the written text in your content are running off the screen. Can someone else please provide feedback and let me know if
    this is happening to them as well? This may be a issue with my
    internet browser because I’ve had this happen previously.
    Thanks

  7. I must thank you for the efforts you have put in penning this site. I’m hoping to see the same high-grade content by you in the future as well. In truth, your creative writing abilities has motivated me to get my own, personal website now 😉

  8. I do not know whether it’s just me or if everyone else experiencing issues with your site.
    It appears like some of the written text within your posts are running off the
    screen. Can somebody else please comment and let me know if this is happening to them
    too? This may be a problem with my web browser because I’ve
    had this happen before. Appreciate it

Leave a Reply

Your email address will not be published.